JP2005509599A - 抗癌組み合わせ - Google Patents

抗癌組み合わせ Download PDF

Info

Publication number
JP2005509599A
JP2005509599A JP2003524567A JP2003524567A JP2005509599A JP 2005509599 A JP2005509599 A JP 2005509599A JP 2003524567 A JP2003524567 A JP 2003524567A JP 2003524567 A JP2003524567 A JP 2003524567A JP 2005509599 A JP2005509599 A JP 2005509599A
Authority
JP
Japan
Prior art keywords
topoisomerase
inhibitors
compound selected
dmxaa
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2003524567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005509599A5 (enExample
Inventor
ウィルソン，ウィリアム・ロバート
シーム，ブロンウィン・ゲイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of JP2005509599A publication Critical patent/JP2005509599A/ja
Publication of JP2005509599A5 publication Critical patent/JP2005509599A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
JP2003524567A 2001-09-03 2002-09-03 抗癌組み合わせ Ceased JP2005509599A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0121285.1A GB0121285D0 (en) 2001-09-03 2001-09-03 Anti-cancer combinations
PCT/GB2002/004025 WO2003020259A2 (en) 2001-09-03 2002-09-03 Combinations of dmxaa and other anti-cancer agents

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009133903A Division JP2009263371A (ja) 2001-09-03 2009-06-03 抗癌組み合わせ
JP2010151115A Division JP2010270124A (ja) 2001-09-03 2010-07-01 抗癌組み合わせ

Publications (2)

Publication Number Publication Date
JP2005509599A true JP2005509599A (ja) 2005-04-14
JP2005509599A5 JP2005509599A5 (enExample) 2006-01-05

Family

ID=9921418

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003524567A Ceased JP2005509599A (ja) 2001-09-03 2002-09-03 抗癌組み合わせ
JP2009133903A Pending JP2009263371A (ja) 2001-09-03 2009-06-03 抗癌組み合わせ
JP2010151115A Pending JP2010270124A (ja) 2001-09-03 2010-07-01 抗癌組み合わせ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009133903A Pending JP2009263371A (ja) 2001-09-03 2009-06-03 抗癌組み合わせ
JP2010151115A Pending JP2010270124A (ja) 2001-09-03 2010-07-01 抗癌組み合わせ

Country Status (23)

Country Link
US (6) US7863322B2 (enExample)
EP (3) EP1759694A3 (enExample)
JP (3) JP2005509599A (enExample)
CN (5) CN100536840C (enExample)
AT (1) ATE415963T1 (enExample)
AU (1) AU2002324143B2 (enExample)
BR (1) BR0212258A (enExample)
CA (1) CA2458459A1 (enExample)
CY (1) CY1110426T1 (enExample)
DE (1) DE60230159D1 (enExample)
DK (1) DK1423105T3 (enExample)
EA (3) EA010857B1 (enExample)
ES (1) ES2321283T3 (enExample)
GB (1) GB0121285D0 (enExample)
IL (1) IL160178A0 (enExample)
IS (1) IS7144A (enExample)
MX (1) MXPA04002004A (enExample)
NO (1) NO20040591L (enExample)
NZ (5) NZ576925A (enExample)
PT (1) PT1423105E (enExample)
SI (1) SI1423105T1 (enExample)
WO (1) WO2003020259A2 (enExample)
ZA (1) ZA200401078B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506020A (ja) * 2005-08-26 2009-02-12 アンティソーマ・ピーエルシー 癌治療のための組み合わせ
JP2010527908A (ja) * 2006-12-19 2010-08-19 サイクラセル リミテッド Ｃｎｄａｃ（２’−シアノ−２’−デオキシ−ｎ４−パルミトイル−１−ベータ−ｄ−アラビノフラノシル−シトシン）及び細胞毒性薬を含む組合せ
JP2016538344A (ja) * 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
JP4638098B2 (ja) * 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド 癌治療
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
EP1311262A4 (en) 2000-07-28 2005-06-01 Cancer Rec Tech Ltd CANCER THERAPY THROUGH COMBINATION THERAPY
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
JP2007511499A (ja) 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
BRPI0614965A2 (pt) * 2005-08-26 2016-09-13 Antisoma Plc método para a modulação de crescimento neoplástico, usos de um composto ou, um sal, éster ou pró-droga farmaceuticamente aceitável do mesmo, de um aglutinante do fator de crescimento endotelial vascular, e de um taxano, formulação farmacêutica, e, kit
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2008335469A1 (en) * 2007-12-13 2009-06-18 Novartis Ag Combinations of therapeutic agents for treating cancer
CN101279967B (zh) * 2008-05-29 2010-11-10 武汉远大制药集团有限公司 一种治疗癌症的三甲基呫吨酮-4-乙酸药物组合物及其用途
EA201500417A1 (ru) * 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
US20100068302A1 (en) * 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
EP2464347A1 (en) * 2009-08-11 2012-06-20 Novartis AG Combinations of vascular disrupting agents with inhibitor of apoptosis proteins antagonists
EP3327148B1 (en) 2010-06-18 2021-03-17 Myriad Genetics, Inc. Methods of predicting the status of brca1 and brca2 genes in a cancer cell
ES2704303T3 (es) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
CN105906602B (zh) * 2011-05-16 2018-07-10 杭州民生药物研究院有限公司 2-(5,6-二甲基呫吨酮-4-基)-乙酸衍生物的制备方法
ES2768344T3 (es) 2011-06-17 2020-06-22 Myriad Genetics Inc Métodos y materiales para evaluar el desequilibrio alélico
JP6325453B2 (ja) 2011-12-21 2018-05-16 ミリアド・ジェネティックス・インコーポレイテッド ヘテロ接合性の消失（ｌｏｓｓｏｆｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
EP2617421A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer
ES2687024T3 (es) 2012-02-23 2018-10-23 Children's Medical Center Corporation Procedimientos para predecir la respuesta contra el cáncer
CA2867434C (en) 2012-06-07 2021-10-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
DK2981624T3 (da) 2013-04-05 2020-03-02 Myriad Genetics Inc Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling
US20160067182A1 (en) * 2013-04-09 2016-03-10 Merrimack Pharmaceuticals, Inc. Methods and compositions for improving outcomes of liposomal chemotherapy
CA2931181C (en) 2013-12-09 2023-01-24 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
DK3686288T3 (da) 2014-08-15 2023-05-22 Myriad Genetics Inc Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens
EP4141127B1 (en) 2021-08-30 2024-10-09 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells
CN115282140B (zh) * 2022-02-07 2024-03-08 南京市儿童医院 Aki治疗剂及dmxaa在制备该治疗剂中的应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2015265A1 (de) 1969-03-29 1970-10-08 Yoshitomi Pharmaceutical Industries Ltd., Osaka (Japan) Arylalkansäuren und Verfahren zu deren Herstellung
US3655470A (en) 1969-03-29 1972-04-11 Toa Gosei Chem Ind Process for the production of a foamed thermoplastic resin sheet
US4565806A (en) * 1981-08-18 1986-01-21 Setaelae Kai M E Composition and method for rational treatment of cancer
FR2516922A1 (fr) 1981-11-25 1983-05-27 Lipha Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant
DE3587500T2 (de) * 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
US5281620A (en) 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
DE3789299T2 (de) 1986-12-23 1994-08-04 Warner Lambert Co Verbindungen mit antitumoralen und antibakteriellen Eigenschaften.
JPH01193227A (ja) 1988-01-29 1989-08-03 Res Dev Corp Of Japan 癌免疫療法補助剤
US5126129A (en) 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
US5075287A (en) 1989-03-03 1991-12-24 Nisshin Oil Mills, Inc. Muramyl peptide derivatives and immunoregulating compositions containing them
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5250296A (en) 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
EP0551200A1 (en) 1992-01-07 1993-07-14 National University Of Singapore Protein phosphatase inhibitors for use in therapy
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
GB9308166D0 (en) * 1993-04-20 1993-06-02 Cancer Res Campaign Tech Cancer therapy
GB9320484D0 (en) 1993-10-05 1993-11-24 Wellcome Found Pharmaceutical combinations
DE4417742A1 (de) * 1994-05-20 1995-11-23 Bayer Ag Nicht-systemische Bekämpfung von Parasiten
US5620875A (en) 1995-02-17 1997-04-15 University Of Portland Transfer of taxol from yew tree cuttings into a culture medium over time
AU5688596A (en) 1995-04-13 1996-10-30 Deutsche Om Arzneimittel Gmbh Anti-cd14 antibodies for use in the induction of il-10 secre tion
WO1996036347A1 (en) 1995-05-17 1996-11-21 Eli Lilly And Company Use of leukotriene antagonists for alzheimer's disease
JPH0940690A (ja) 1995-05-23 1997-02-10 Yutaka Sashita ステロイド配糖体及びこれを有効成分とする医薬
AU6714396A (en) 1995-07-28 1997-02-26 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders
US5977077A (en) 1995-08-28 1999-11-02 Interlab Corporation Xanthone analogs for the treatment of infectious diseases
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
AU5792398A (en) 1996-12-13 1998-07-03 Eli Lilly And Company Leukotriene antagonists for treatment or inhibition of gout
CA2274908A1 (en) 1996-12-13 1998-06-18 Eli Lilly And Company Leukotriene antagonists for cerebral focal stroke
UA47505C2 (uk) 1996-12-13 2002-07-15 Елі Ліллі Енд Компані Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну
CA2281570C (en) 1997-03-11 2003-09-23 Les Laboratoires Aeterna Inc. Composition for treating tumors containing shark cartilage extracts and anti-neoplastic agents
US5914340A (en) 1997-03-21 1999-06-22 Eli Lilly And Company Leukotriene antagonists useful for treating dermatoses
WO1998042650A2 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating cystic fibrosis
US5910505A (en) 1997-03-21 1999-06-08 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma
US5998454A (en) 1997-03-21 1999-12-07 Eli Lilly And Company Leukotriene antagonists useful for treating iritis
WO1998042335A1 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating gout
WO1998042345A1 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating cerebral focal stroke
WO1998042336A1 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating gingivitis
WO1998042346A1 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating ischemia reperfusion injury
DE19721211A1 (de) 1997-05-21 1998-11-26 Lindner Sen Wolfgang Dr Med Kombination von antientzündlichen Wirkstoffen mit immunstimulierenden Agentien und zytotoxischen Agentien zur Behandlung von Tumoren
IL141627A0 (en) 1998-08-24 2002-03-10 Maxim Pharm Inc Activation and protection of t-cells (cd4+and cd8+) using an h2 receptor agonist and other t-cell activating agents
CA2343133A1 (en) 1998-09-10 2000-03-23 Magainin Pharmaceuticals, Inc. Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
DE60018225T2 (de) 1999-03-01 2005-12-29 Pfizer Products Inc., Groton Oxamsäuren mit einer Cyanogruppe als Liganden für den Thyroidrezeptor
JP4638098B2 (ja) 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド 癌治療
US6806257B1 (en) 1999-10-20 2004-10-19 Board Of Trustees Of Southern Illinois University Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
EP1231939A2 (en) 1999-11-11 2002-08-21 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034198A2 (en) 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
IL148579A0 (en) 1999-11-11 2002-09-12 Lilly Co Eli Oncolytic combinations for the treatment of cancer
AU1916501A (en) 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
CA2400197A1 (en) 2000-02-17 2001-08-23 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
JP2001247459A (ja) * 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
EP1311262A4 (en) 2000-07-28 2005-06-01 Cancer Rec Tech Ltd CANCER THERAPY THROUGH COMBINATION THERAPY
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
GB0321999D0 (en) 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
GT200500186A (es) * 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
BRPI0614965A2 (pt) 2005-08-26 2016-09-13 Antisoma Plc método para a modulação de crescimento neoplástico, usos de um composto ou, um sal, éster ou pró-droga farmaceuticamente aceitável do mesmo, de um aglutinante do fator de crescimento endotelial vascular, e de um taxano, formulação farmacêutica, e, kit
GB0517387D0 (en) 2005-08-26 2005-10-05 Antisoma Res Ltd Combinations for the treatment of cancer
MX2010003594A (es) 2007-10-23 2010-09-22 Antisoma Res Ltd Formas cristalinas de sal sodica de dmxaa.

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6009009823, ＳＩＥＭＡＮＮ，Ｄ．Ｗ． ｅｔ ａｌ, "Ｐｏｔｅｎｔｉａｔｉｏｎ ｏｆ ｃｈｅｍｏｔｈｅｒａｐｙ ｂｙ ｖａｓｃｕｌａｒ ｔａｒｇｅｔｉｎｇ ａｇｅｎｔｓ", Ｂｒｉｔｉｓｈ Ｊｏｕｒｎａｌ ｏｆ Ｃａｎｃｅｒ, 1999, Ｖｏｌ．８０， Ｎｏ．ＳＵＰＰＬ, ｐ．９０ *
JPN6009009824, ＨＩＬＬ，Ｓ．Ａ． ｅｔ ａｌ, "Ａｎｔｉ−ｖａｓｃｕｌａｒ ａｐｐｒｏａｃｈｅｓ ｔｏ ｓｏｌｉｄ ｔｕｍｏｕｒ ｔｈｅｒａｐｙ： ｅｖａｌｕａｔｉｏｎ ｏｆ ｖｉｎｂｌａｓｔｉｎｅ ａｎｄ ｆｌａｖｏｎｅ ａｃｅｔｉｃ ａｃｉｄ", Ｉｎｔ Ｊ Ｃａｎｃｅｒ, 1995, Ｖｏｌ．６３， Ｎｏ．１, ｐ．１１９−２３ *
JPN6009037653, 佐々木 常雄, "Ｂｉｏｃｈｅｍｉｃａｌ Ｍｏｄｕｌａｔｉｏｎの研究の現状", 医学のあゆみ, 1993, Ｖｏｌ．１６４， Ｎｏ．５, ｐｐ２５１−２５４ *
JPN7009001126, ＧＨＡＥＭＭＡＧＨＡＭＩ，Ｍ． ｅｔ ａｌ, "Ｎｅｗ ａｇｅｎｔｓ ｉｎ ｔｈｅ ｔｒｅａｔｍｅｎｔ ｏｆ ｓｍａｌｌ ｃｅｌｌ ｌｕｎｇ ｃａｎｃｅｒ", Ｃｈｅｓｔ, 1998, Ｖｏｌ．１１３， Ｎｏ．１ Ｓｕｐｐｌ, ｐ．８６Ｓ−９１Ｓ *
JPN7009003528, ＫＥＬＬＹ，Ｋ．, "Ｎｅｗ ｃｈｅｍｏｔｈｅｒａｐｙ ａｇｅｎｔｓ ｆｏｒ ｓｍａｌｌ ｃｅｌｌ ｌｕｎｇ ｃａｎｃｅｒ", Ｃｈｅｓｔ, 2000, Ｖｏｌ．１１７， Ｎｏ．４ Ｓｕｐｐｌ １, ｐ．１５６Ｓ−１６２Ｓ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506020A (ja) * 2005-08-26 2009-02-12 アンティソーマ・ピーエルシー 癌治療のための組み合わせ
JP2010527908A (ja) * 2006-12-19 2010-08-19 サイクラセル リミテッド Ｃｎｄａｃ（２’−シアノ−２’−デオキシ−ｎ４−パルミトイル−１−ベータ−ｄ−アラビノフラノシル−シトシン）及び細胞毒性薬を含む組合せ
JP2016538344A (ja) * 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用

Also Published As

Publication number Publication date
US7863322B2 (en) 2011-01-04
EP1423105B9 (en) 2009-08-12
JP2009263371A (ja) 2009-11-12
JP2010270124A (ja) 2010-12-02
DK1423105T3 (da) 2009-03-30
EP1759694A3 (en) 2009-02-18
EA008056B1 (ru) 2007-02-27
US7868039B2 (en) 2011-01-11
SI1423105T1 (sl) 2009-08-31
NZ576925A (en) 2010-07-30
EP1423105B1 (en) 2008-12-03
US20070060637A1 (en) 2007-03-15
ES2321283T3 (es) 2009-06-04
CY1110426T1 (el) 2015-04-29
US20080070847A1 (en) 2008-03-20
CN1708296A (zh) 2005-12-14
CN101596186A (zh) 2009-12-09
AU2002324143B2 (en) 2007-09-13
EP1759694A2 (en) 2007-03-07
US7868040B2 (en) 2011-01-11
NZ531045A (en) 2006-08-31
US7863321B2 (en) 2011-01-04
EP2236134A1 (en) 2010-10-06
ATE415963T1 (de) 2008-12-15
EA010857B1 (ru) 2008-12-30
EA200400370A1 (ru) 2004-08-26
NZ567456A (en) 2009-08-28
NZ554093A (en) 2008-07-31
CN101596187A (zh) 2009-12-09
DE60230159D1 (de) 2009-01-15
MXPA04002004A (es) 2005-02-17
CN100536840C (zh) 2009-09-09
US7863320B2 (en) 2011-01-04
GB0121285D0 (en) 2001-10-24
US20080070849A1 (en) 2008-03-20
EA200601118A1 (ru) 2006-12-29
CN1994287A (zh) 2007-07-11
CN101607087A (zh) 2009-12-23
EA200801611A1 (ru) 2009-06-30
IS7144A (is) 2004-02-06
US20080070848A1 (en) 2008-03-20
WO2003020259A3 (en) 2003-04-17
CA2458459A1 (en) 2003-03-13
WO2003020259A2 (en) 2003-03-13
EP1423105A2 (en) 2004-06-02
US20080070886A1 (en) 2008-03-20
ZA200401078B (en) 2005-04-15
BR0212258A (pt) 2004-10-19
US20040204480A1 (en) 2004-10-14
NO20040591L (no) 2004-04-30
PT1423105E (pt) 2009-03-09
IL160178A0 (en) 2004-07-25
NZ546573A (en) 2007-05-31

Similar Documents

Publication Publication Date Title
JP2009263371A (ja) 抗癌組み合わせ
AU2002324143A1 (en) Combinations of dxmaa and other anti-cancer agents
JP2002543112A (ja) アントラサイクリン誘導体を含有する配合製剤
WO1999048503A1 (en) Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate
MX2008014404A (es) Tratamientos anticancer con combinacion de docetaxel y ecteinascidin.
AU740642B2 (en) Pharmaceutical compositions containing cinchonine dichlorhydrate
AU2007202083B2 (en) Anti-Cancer Combinations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091023

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091130

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100702

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100902

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110118

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20110520